Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The Global Generics and Biosimilars Awards celebrate the greatest achievements and innovations across the development, authorisation, marketing and distribution of global off-patent pharmaceuticals. Co-locating with CPhI Worldwide in Frankfurt, these illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognised across 14 categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and Business Development of the Year.
The Global Generics and Biosimilars Awards are free to enter. The closing date for entries is 19 August 2022, and the qualifying period for submissions is 1 July 2021 - 31 July 2022. The judging process will take place over the summer. The finalists will be announced in September and the winners revealed at the Awards on 2 November 2022.
Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business. There are awards for the following regions: Americas / EMEA / Asia-Pacific.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or Intermediates.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
This category allows generics, biosimilars and value-added medicines firms as well as their partnering law firms to highlight outstanding results from their approach to intellectual property and their legal strategy. This could include notable litigation results allowing a competitive advantage or early launch; inventive ways of getting around or invalidating intellectual property; obtaining intellectual property to protect their own products or processes; or ways in which legal strategies or IP approaches from different global jurisdictions have been used as a template elsewhere, showing the benefits of a coordinated international IP strategy.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Awarded to recognise outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract manufacturers, law firms and consultants.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Aurelio Arias
Aaron Barkoff
Craig Burton
Stuart Colligon
Frances Cloud
Duncan Emerton
Maja Graf
Chloe Kent
Suzette Kox
Ewan Livesey
Doug Long
Axel Muller
Julie Reed
Dean Rudge
Alan Sheppard
Adrian Van Der Hoven
James Vane Tempest
David Wallace
Aurelio creates topical and forward-looking strategic content relevant to pharma executives worldwide and publishes articles, blogs, and white papers on a regular basis. Aurelio’s predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on various topics relevant to the pharmaceutical industry. He is considered a subject matter expert in several areas and speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects.Prior to IQVIA, Aurelio has worked in R&D and in various strategy consulting roles. He holds an MSci in Chemistry from Imperial College London.
Craig Burton is the Senior Vice President of Policy and Strategic Alliances for the Association for Accessible Medicines and the Executive Director of the Biosimilars Council. In his current role, Craig is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups. With more than 20 years of Federal health policy experience, Craig has served in key roles at the center of a range of pressing health care debates. Prior to joining AAM in 2017, Craig was at Avalere Health, where he helped clients anticipate and plan for the impact of change stemming from legislative, regulatory, or other market dynamics. Craig also established and directed the health policy and government relations efforts for two biopharmaceutical companies. Craig served as Deputy Assistant Secretary for Legislation in the U.S. Department of Health and Human Services. In this role, he advised the Secretary, senior Department leaders and White House officials on legislative strategy to achieve key priorities. Craig also served in the Senate, where he was Health Policy Advisor to Senate Majority Leader Bill Frist, M.D., and as professional staff on the U.S. Senate Committee on Health, Education, Labor and Pensions.
Stuart founded Panacea in 2008 after several years of working in the generics arm of the Pharma industry. Panacea provides pharmacovigilance, regulatory affairs and quality assurance services to the industry globally. He has gained experience in board positions of a range of companies over a 30 year career, with particular focus on strategic direction, change management, business development and corporate communication.
Maja Graf is a Policy & Science Manager at Medicines for Europe and coordinator of Value Added medicines sector group. Maja is pharmacists by training. Before joining Medicines for Europe, she worked in the pharmaceutical industry, working on the off-patent development projects liaising with the external partners across the industry. Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries. As a leading partner for better healthcare aims to increase the health and wellbeing of all Europeans through better access to high-quality medicines.
Suzette Kox is the first Secretary General of the International Generic and Biosimilar Medicines Association. She was nominated in January 2019, after 17 years in various functions at Medicines for Europe. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. Before joining the generic medicines industry in 1992, Suzette followed a hospital and retail pharmacy career. Along with a degree in pharmacy (Paris), she holds a postgraduate diploma in anatomy-pathology (Cochin Port Royal, Paris).
Ewan is corporate and business development leader and qualified lawyer with over 25 years’ experience in the pharmaceutical industry with roles ranging from General Counsel to Chief Business Officer for global pharmaceutical companies. He has worked for some of the leading generic companies including IVAX, Lupin, Glenmark, Apotex and most recently Zentiva where he led the acquisition of Alvogen’s CEE business (acquisition of the year 2020). Ewan currently works as a consultant to several companies and PE firms advising on corporate strategy including all elements of business development from acquisition to licensing and portfolio selection.
Co-founder and CEO of nucleo (www.go-nucleo.com)
Doug Long is Vice President of Industry Relations at IQVIA (formerly QuintilesIMS) one the world’s largest pharmaceutical information company. IQVIA offers services to the pharmaceutical industry in over 101 countries around the globe. Doug has been with IQVIA since 1989. His fundamental task is to help secure data for all existing and new databases supported by IQVIA, manage supplier, manufacturer & association relationships, and develop information for data partners. As direct consequence of his involvement in these areas, Doug has considerable experience with, and a unique perspective on, the changing U.S. and global healthcare marketplace and pharmaceutical distribution.
By education a pharmacist with a PhD in Pharmaceutical Technology - worked for over 25 years for STADA Arzneimittel AG in very different business areas like General Management, Operations, M&A, M&S and Communications. Finally, he was appointed as STADA Executive Board Member for Production and Development from 2010 to 2013. Since 2014 Axel is working as Consultant – mainly but not only in the Pharmaceutical Industry. After some years working as Senior Advisor of Arthur D. Little he joined 2018 Fidelio Healthcare Partners as Associated Partner. In addition, Axel is non-executive member of several supervisory and advisory boards.
Juliana (Julie) Reed currently serves as the Executive Director of the Biosimilars Forum, leading strategy for the group’s strategic efforts to increase access to and adoption of biosimilars. Reed served as the Forum’s President for more than eight years and was one of its founders. As the Biosimilars Forum President, Reed oversaw advocacy and awareness campaigns to advance biosimilar access and adoption in the United States. She brings more than 30 years of experience in the healthcare sector to the Forum. Most recently, Reed was Vice President and Global Corporate Affairs Lead with Pfizer, specializing in immunology, inflammation and biosimilars portfolios. She also has experience in executive roles leading global corporate and government affairs for Hospira and Coherus BioSciences.
Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, to foster market access for generic, biosimilar and value added medicines, to support policy measures for sustainable pricing, to promote high regulatory standards while ensuring that the associated costs can be integrated into market dynamics and to develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.
Sponsorship of the Global Generics & Biosimilars Awards provides exclusive opportunities, targeted branding, thought leadership and lead generation. Seize the opportunity to come together, to educate and engage with the companies who matter to you most.
Sponsor Opportunities
Looking to attend the Global Generics & Biosimilars Awards? Book your table today for the awards!
BOOK YOUR TABLE
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com
Aurobindo’s mission is to become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.
In addition to being the market leader in Semi-Synthetic Penicillin’s, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics.
Through cost effective manufacturing capabilities and a few loyal customers, the company also entered the high margin specialty generic formulations segment. Today Aurobindo Pharma has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. A well-integrated pharma company, Aurobindo Pharma features among the top 2 Pharmaceutical companies in India in terms of consolidated revenues. Aurobindo exports to over 150 countries across the globe
In 1977, biochemist Silvia Gold and doctor Hugo Sigman founded Insud Pharma, transforming their lifelong vocation into a robust, integrated, global business dedicated entirely to caring for people's health and wellbeing. Today, we are a pharmaceutical group with a track record spanning over 40 years and a footprint in more than 45 countries, led by Leandro and Lucas Sigman. Our overarching goal is to improve people's health all over the world, providing accessible, effective, safe, quality medicines through our various business units, underpinned by continuous investment in R&D and cutting-edge technology at all our centres.
Since its foundation in 2009, Pharmacloud has steadily built up its reputation as a provider of specialist advice and consultancy to both the pharma industry and financial investors. We offer a number of services, with a particular focus on commercial due diligence on off-patent products. However, we also work with big pharma companies on generic defence strategies, as well as with emerging pharma companies seeking to assess the potential market for their value-added generic products or biosimilars.
The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.
Pharmawise is a leading boutique consulting firm focused on generic and biosimilar market expertise. Since 2006, we have conducted 150+ projects for leading financial institutions, generic and pharmaceutical companies, spanning:
We match deep know-how and know-who to your generic or biosimilar needs: our project teams include highly knowledgeable experts with ~20 years executive experience and networks at successful global or local generic companies and leading management consulting firms in the above-mentioned areas.
SanaClis is a full-service Global CRO with a fully integrated clinical supply chain, thereby offering a comprehensive range of end-to-end services for clinical trials. SanaClis was founded in 2000 by seasoned industry experts, all of whom have had executive level positions in leading pharma companies and large global CROs.
SanaClis has vast experience of successfully running studies for various sized sponsors, ranging from virtual biotech’s through to top ten pharma companies, both in terms of its CRO services and Clinical supply services. Every project is a fundamental priority for the SanaClis, irrespective of the size or scope. SanaClis believes that every company and professional should receive an extremely high level of quality and clinical excellence applied to its projects. SanaClis prides itself upon its esteemed track record of successfully delivering various projects on time and on budget, ensuring quality, expertise and responsiveness resonates throughout the entire project duration.
Whilst SanaClis offers the provisions of our services across all therapeutic areas and geographic locations (entire Europe, UK, Asia and USA), SanaClis has a substantial and unique expertise in Central and Eastern European countries, regions of which provide an abundance of advantages, from high recruitment rates through to high quality of data. In addition to being a full service CRO, SanaClis is one of the very few service providers with an extensive range of in-house logistics and clinical supply capabilities. SanaClis has a portfolio of privately owned GMP and GDP certified storage and distribution depots, strategically located across the EU, US and further Eastern European countries.
CRO services include:
Further in-house supply chain services include:
This unique and fully comprehensive service offering allows SanaClis to streamline the entire project from end-to-end, thereby creating cost efficiencies, whilst maintaining a high level of quality at all times
STADA is a leading manufacturer of high-quality pharmaceuticals. With a long-standing heritage rooted in pharmacies, we are perceived as a reliable and trustworthy partner for more than 125 years. With our products we help people protect and regain a dignified and able life. With our proven Generics, we ensure that everyday health remains affordable. To our employees, we offer an attractive working environment in which they can develop personally.
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.
International Generic and Biosimilar Medicines Association
Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.
